Lovly Christine M

基本信息

浏览量：75

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 330 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Refining Neoadjuvant Immunotherapy for Resectable Lung Cancer

Misty D. Shields,Christine M. Lovly

NATURE MEDICINEno. 6 (2024): 1535-1536

引用0浏览0WOSNATURE引用

1298P Epidemiological and Genomic Features of Patients (pts) with Advanced/metastatic (a/m) Non-Small Cell Lung Cancer (NSCLC) with HER2/ERBB2 Mutations Within and Outside the Tyrosine Kinase Domain (TKD)

X. Le,C.S. Baik, M. Nagasaka,T. Patil, S.S. Maruti,S. Stanhope, N.A. Kaya, S. Herbertz,C.M. Lovly

Annals of Oncology (2024)

引用0浏览0引用

Abstract 1221: Selective Translational Activation of PBK (PDZ- Binding Kinase) Reveals a Molecular Vulnerability of Drug-Tolerant Persister Cells to Targeted Therapies in EGFR-mutant Lung Adenocarcinoma

Camille Leonce,Anne-Laure Desage,Nour El-Houda Mourksi,Genevieve De Souza,Beatrice Vanbervliet, Camille Charrondiere, Constance Nicq, Jeremy Neri,Aurelie Swalduz,Laurie Tonon, Eric Cumunel,Nicolas Gadot,Gabriel Ichim, Jean-Jacques Diaz,Christine Lovly,Julien Mazieres,Mayeul Tabutin,Maurice Perol,Sylvie Lantuejoul,Olivier Calvayrac,Fabien Forest,Virginie Marcel,Pierre Saintigny,Sandra Ortiz-Cuaran

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network : JNCCNno. 4 (2024): 249-274

引用0浏览0WOS引用

Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-Small Cell Lung Cancer: the Phase II TRUST-I Study

Wei Li,Anwen Xiong,Nong Yang,Huijie Fan,Qitao Yu,Yanqiu Zhao,Yongsheng Wang,Xue Meng,Jingxun Wu,Ziping Wang,Yunpeng Liu,Xicheng Wang,Xintian Qin,Kaihua Lu,Wu Zhuang, Yizhong Ren, Xianyu Zhang, Bing Yan,Christine M. Lovly,Caicun Zhou

JOURNAL OF CLINICAL ONCOLOGYno. 22 (2024)

引用0浏览0WOS引用

NCCN Guidelines® Insights: Mesothelioma: Pleural, Version 1.2024

Journal of the National Comprehensive Cancer Network : JNCCN（2024）

引用0浏览0WOS引用

New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 Years

Christine M Lovly

Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 29 (2024): 3383-3386

引用0浏览0WOS引用

Abstract 3460: Predicting Cessation of Immune Checkpoint Inhibitor Therapy Due to Severe Adverse Events with an Integrated Autoimmune Disease Polygenic Risk Score

Pooja Middha,Rohit Thummalapalli,Zoe Quandt,Matthew A. Gubens,Christine M. Lovly,Geoffrey Liu,Melinda C. Aldrich,Adam J. Schoenfeld,Elad Ziv

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn

副教授

论文共 330 篇作者统计合作学者相似作者